James R. Gavin

James R. Gavin

Auto-generated profile, based on publicly available information

James R. Gavin

Emory University School of Medicine, Atlanta, GA, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2018 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
YKYogish C Kudva
Yogish C Kudva
AAAndrew J Ahmann
Andrew J Ahmann
RBRichard M Bergenstal
Richard M Bergenstal
JGJames R Gavin
James R Gavin
DKDavida F Kruger
Davida F Kruger
DHDennis R Harris
Dennis R Harris
The use of personal continuous glucose monitoring (CGM) has expanded dramatically among individuals with diabetes. CGM systems provide retrospective data, as well as the current glucose value and trend arrow data, which indicate the direction and velocity of changing glucose. In 2017, Aleppo and colleagues developed a simplified approach for adults with diabetes to safely adjust rapid-acting insulin doses using trend arrow information in the Dexcom G5 CGM system. Since that time, the FreeStyle Libre and FreeStyle Libre 14 day CGM systems have become available in the United States; however, guidance on using trend arrow data that take the unique features of these systems into consideration is lacking. Specifically, the FreeStyle Libre systems do not have automatic alarms, which impact how the system and trend arrow data are used. Endocrine Society convened an expert panel to address this gap and develop an approach to adjusting rapid-acting insulin doses for adults using trend arrows in the FreeStyle Libre systems. We based our approach on previous work and expanded upon engagement and scanning recommendations as well as incorporate pre-exercise planning specific to these systems. Our approach provides insulin dose adjustments as discrete insulin units based on an individual’s insulin sensitivity and directionality of the trend arrow. We focus on the needs of patients treated by multiple daily injection because these individuals currently make up a greater proportion of individuals on intensive insulin therapy. Our recommendations are intended to provide a safe, practical approach to using trend arrows in the FreeStyle Libre systems.

12 April 2024 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
JGJames R. Gavin
James R. Gavin
HRHelena W Rodbard
Helena W Rodbard
TBTadej Battelino
Tadej Battelino
FBFrank Brosius
Frank Brosius
ACAntonio Ceriello
Antonio Ceriello
OSOliver Schnell
Oliver Schnell

1 January 2007 in US Endocrinology
Verified
Journal Article
Open access
JGJames R Gavin
James R Gavin
It is estimated that diabetes, both type 1 and type 2, currently affects more than 195 million people worldwide. This figure is expected to rise to more than 330 million by 2030.1,2 The rise in type 1 diabetes has been linked to changing environmental factors,3 while the rise in type 2 diabetes is strongly associated with increasing rates of obesity.4